Literature DB >> 14742235

Penetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administration.

E García Vázquez1, J Mensa, Y López, P Díaz Couchard, D Soy, J R Fontenla, M Sarasa, X Carné, E Montull.   

Abstract

We determined the linezolid concentrations in serum samples and aqueous humors (AHs) from 21 patients undergoing cataract extraction. Cataract removal was performed at various times (from 60 to 270 min) after the end of a 30-min infusion of 600 mg of linezolid. Serum samples were obtained 1 h after the end of linezolid administration to determine the maximum concentration of linezolid (C(max)); AHs and a second serum sample were taken simultaneously during the operation, and the concentrations of linezolid in AH (C(AH)) and serum (C(S)) were determined. The mean C(AH) 1 h after linezolid administration was 4.94 micro g/ml, and the mean ratio of C(AH) to C(S) (R = C(AH)/C(S)) was 0.43. All patients had a C(AH) of >2 micro g/ml, which was higher than the MIC at which 90% of Staphylococcus epidermidis strains are inhibited.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742235      PMCID: PMC321529          DOI: 10.1128/AAC.48.2.670-672.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Postoperative endophthalmitis: incidence, predisposing surgery, clinical course and outcome.

Authors:  S Somani; A Grinbaum; A R Slomovic
Journal:  Can J Ophthalmol       Date:  1997-08       Impact factor: 1.882

2.  Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis.

Authors:  M G Speaker; F A Milch; M K Shah; W Eisner; B N Kreiswirth
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

Review 3.  Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions.

Authors:  Michelle C Callegan; Michael Engelbert; David W Parke; Bradley D Jett; Michael S Gilmore
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

4.  Endophthalmitis following penetrating eye injuries.

Authors:  A M Duch-Samper; J L Menezo; M Hurtado-Sarrió
Journal:  Acta Ophthalmol Scand       Date:  1997-02

5.  Human vitreous levels of selected antistaphylococcal antibiotics.

Authors:  J L Axelrod; R M Klein; R L Bergen; M Z Sheikh
Journal:  Am J Ophthalmol       Date:  1985-10-15       Impact factor: 5.258

6.  Microbial endophthalmitis resulting from ocular trauma.

Authors:  J C Affeldt; H W Flynn; R K Forster; S Mandelbaum; J G Clarkson; G D Jarus
Journal:  Ophthalmology       Date:  1987-04       Impact factor: 12.079

Review 7.  Quinupristin-dalfopristin and linezolid: evidence and opinion.

Authors:  George M Eliopoulos
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

Review 8.  Linezolid: the first oxazolidinone antimicrobial.

Authors:  Robert C Moellering
Journal:  Ann Intern Med       Date:  2003-01-21       Impact factor: 25.391

  8 in total
  4 in total

1.  Penetration of levofloxacin into the anterior chamber (aqueous humour) of the human eye after intravenous administration.

Authors:  E García-Vázquez; J Mensa; M Sarasa; Y López; P D Couchard; D Soy; J R Fontenla
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-02       Impact factor: 3.267

Review 2.  Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.

Authors:  Ana Maria Rivera; Helen W Boucher
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

3.  The pharmacokinetics of linezolid in the non-inflamed human eye.

Authors:  J I Prydal; D R Jenkins; A Lovering; A Watts
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

4.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.